Sofinnova Partners announced that Zambon is acquiring its portfolio company Breath Therapeutics for as much as €500 million. Sofinnova Partners will exit Breath Therapeutics after a holding period of two and a half years.   “Breath Therapeutics is a perfect symbol of our investment strategy: cutting-edge platform and products developed by brilliant entrepreneurs for a debilitating disease with no effective treatment,” said Graziano Seghezzi, managing partner, Sofinnova Partners and Breath ...